corticosteroid News
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been ...
-
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. ...
-
Lyra Therapeutics To Present Lantern Phase 2 Study Results For Lyr 210 In Oral Presentation At Cosm 2021 Virtual
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate ...
-
Accelerating Lupus Drug Discovery & Development - Fireside Chat with Experts in SLE Research
Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. SLE is extremely ...
-
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) published an average selling price (ASP) for the Company’s SINUVA sinus implant, providing predictability, transparency, and confidence of reimbursement for ...
-
Who can benefit from an adjustable gastric band implant?
Who can benefit from an adjustable gastric band implant? Adults between the ages of 18 and 60 years with morbid obesity (BMI of > 40) or severe obesity (BMI of > 35) with at least one complication (diabetes, hypertension, sleep apnea syndrome, joint disorders) People who have already tried to lose weight without success despite receiving specialized medical care for several months ...
-
InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy
InGeneron, Inc., a regenerative medicine and cell therapy company, announced today the enrollment of the first patients in a pivotal study evaluating InGeneron’s cell therapy as a way to treat partial thickness rotator cuff tears involving a partial tear in the supraspinatus tendon. The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of the ...
-
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed ...
By Benevolent
-
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® And Atectura® Breezhaler® In Alberta
First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon 85% private payer health plan coverage across Canada Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into ...
-
Preventing Wound Infections and Complications at Urgent Care
Cuts and lacerations are among the most common complaints that bring patients to urgent care clinics. Whether a wound originates from an accident with a sharp object, such as a kitchen knife or yard tool, or from a blunt force such as a fall, there may be a risk of infection. Urgent care providers are responsible for providing treatment that promotes healing and helps prevent wound infection. ...
-
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® And Atectura® Breezhaler® In Quebec And Nova Scotia
Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. More than 90% private insurance coverage across Canada Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is proud to announce a major milestone for its two innovative Asthma ...
-
World Health Organization Panel Strongly Recommends The Use Of Baricitinib To Treat Hospitalised Patients With COVID-19
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able to rapidly pinpoint ...
By Benevolent
-
Zerigo Health Raises $43M in Series B Funding
San Diego, CA, October 21, 2021 –Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced a $43 million Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer. The round also included participation by existing ...
-
Topline results from Phase 3 SPRINTER trial
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
-
Dexamethasone reportedly part of President Trump’s Treatment
As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute disease. The use of higher dexamethasone doses, with potentially additional and desired immunological effects, is limited due the presence of toxic ...
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, ...
-
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101 ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate In a previous trial, EsoCap’s proprietary and unique targeted application ...
By EsoCap AG
-
MediPrint™ Ophthalmics Announces Promising Results From Its Primary Market Research
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. Key learnings from the market ...
-
LayerBio Awarded $3M from U.S. Department of Defense (DoD) to Advance OcuRing for Cataract Surgery
OcuRing is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. $3M DoD award will fund IND-enabling toxicology and manufacturing activities. LayerBio plans to develop OcuRing products for multiple cataract surgery-related indications. OcuRing™ is a novel sustained-release technology designed to deliver therapies to ...
-
Neurent Medical`s RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan
Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues LONDON, Nov. 13, 2018 /CNW/ -- Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises Neurent Medical with the 2018 European New Product Innovation Award for developing a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you